BG
Bellevue Group Portfolio holdings
AUM
$4.54B
1-Year Return
22.5%
This Quarter Return
+0.5%
1 Year Return
+22.5%
3 Year Return
+98.22%
5 Year Return
+159.37%
10 Year Return
–
AUM
$9.7B
AUM Growth
-$152M
(-1.5%)
Cap. Flow
+$254M
Cap. Flow
% of AUM
2.62%
Top 10 Holdings %
Top 10 Hldgs %
29.73%
Holding
233
New
14
Increased
60
Reduced
64
Closed
42
Top Buys
| 1 |
CareDx
CDNA
|
$65.3M |
| 2 |
Abbott
ABT
|
$50.4M |
| 3 |
Molina Healthcare
MOH
|
$46.5M |
| 4 |
Danaher
DHR
|
$44.5M |
| 5 |
Medtronic
MDT
|
$34M |
Top Sells
| 1 |
HRC
HILL-ROM HOLDINGS, INC.
HRC
|
$63.1M |
| 2 |
Centene
CNC
|
$40.7M |
| 3 |
Baxter International
BAX
|
$40.6M |
| 4 |
Hologic
HOLX
|
$22.3M |
| 5 |
DexCom
DXCM
|
$15.4M |
Sector Composition
| 1 | Healthcare | 97.85% |
| 2 | Technology | 0.8% |
| 3 | Industrials | 0.75% |
| 4 | Communication Services | 0.02% |
| 5 | Energy | 0.01% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
126
Harmony Biosciences
HRMY
$2.07B
| $5.17M | 0.05% |
121,161
-8,128
| -6% | -$347K |
|
127
Neuropace
NPCE
$322M
| $5.12M | 0.05% |
507,930
| – | – |
|
|
BNR
128
Burning Rock Biotech
BNR
$89.4M
| $4.67M | 0.05% |
48,989
| – | – |
|
|
GTH
129
DELISTED
Genetron Holdings Limited ADS
GTH
| $4.41M | 0.05% |
241,046
| – | – |
|
130
Procept Biorobotics
PRCT
$2.26B
| $4.34M | 0.04% |
173,649
+23,649
| +16% | +$591K |
|
|
OLK
131
DELISTED
Olink Holding AB (publ) American Depositary Shares
OLK
| $4.28M | 0.04% |
235,273
+37,746
| +19% | +$687K |
|
132
Arcus Biosciences
RCUS
$1.3B
| $3.54M | 0.04% |
87,500
-7,200
| -8% | -$291K |
|
133
Johnson & Johnson
JNJ
$430B
| $3.46M | 0.04% |
20,200
-10,300
| -34% | -$1.76M |
|
134
AstraZeneca
AZN
$253B
| $3.44M | 0.04% |
+59,000
| New | +$3.44M |
|
|
BCYC
135
Bicycle Therapeutics
BCYC
$496M
| $3.27M | 0.03% |
53,700
-12,000
| -18% | -$731K |
|
|
MRTX
136
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $3.17M | 0.03% |
21,600
+2,700
| +14% | +$396K |
|
137
Kymera Therapeutics
KYMR
$3.11B
| $3.11M | 0.03% |
49,000
+13,500
| +38% | +$857K |
|
138
Seer Inc
SEER
$118M
| $3.11M | 0.03% |
136,133
| – | – |
|
|
CTLT
139
DELISTED
CATALENT, INC.
CTLT
| $2.96M | 0.03% |
23,100
-12,900
| -36% | -$1.65M |
|
|
BPMC
140
DELISTED
Blueprint Medicines
BPMC
| $2.73M | 0.03% |
+25,500
| New | +$2.73M |
|
141
Labcorp
LH
$23.2B
| $2.66M | 0.03% |
9,836
-41,496
| -81% | -$11.2M |
|
142
Quest Diagnostics
DGX
$20.5B
| $2.64M | 0.03% |
15,250
+2,250
| +17% | +$389K |
|
|
SYNH
143
DELISTED
Syneos Health, Inc. Class A Common Stock
SYNH
| $2.21M | 0.02% |
21,500
-35,500
| -62% | -$3.65M |
|
|
INBX
144
DELISTED
Inhibrx, Inc. Common Stock
INBX
| $2.21M | 0.02% |
+50,500
| New | +$2.21M |
|
145
Xencor
XNCR
$610M
| $2.09M | 0.02% |
52,100
| – | – |
|
146
Eli Lilly
LLY
$652B
| $2.09M | 0.02% |
+7,552
| New | +$2.09M |
|
147
Intellia Therapeutics
NTLA
$1.29B
| $1.96M | 0.02% |
16,594
| – | – |
|
148
Ultragenyx Pharmaceutical
RARE
$3.07B
| $1.77M | 0.02% |
21,000
-6,900
| -25% | -$580K |
|
149
Zoetis
ZTS
$67.9B
| $1.73M | 0.02% |
7,100
| – | – |
|
150
Arcturus Therapeutics
ARCT
$485M
| $1.54M | 0.02% |
41,600
+7,100
| +21% | +$263K |
|